July 28, 2014
Macrocure, a late-stage Israeli biotech developing white blood cell injections to treat hard-to-heal and chronic wounds, has announced terms for its $75 million IPO. The Petach Tikva company is offering 5.4 million shares, according to Renaissance Capital Investments.
Macrocure’s main product is CureXcell, a cell based therapy that when applied to a wound, restores the natural balance required for the wound healing process.
CureXcell has been approved as a medical device in Israel and has been used in more than 5,000 patients in commercial or clinical study settings with consistent results, according to Macrocure data.
Fighting for Israel's truth
We cover what makes life in Israel so special — it's people. A non-profit organization, ISRAEL21c's team of journalists are committed to telling stories that humanize Israelis and show their positive impact on our world. You can bring these stories to life by making a donation of $6/month.
